Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles
NEUROLOGY 2004;63:1346-1347
© 2004 American Academy of Neurology

October 26 Highlights

Expanding the molecular classification of dementias


Cairns et al. describe the clinical and neuropathologic features of 10 patients with neuronal intermediate filament inclusion disease (NIFID). Their cases have features of both frontotemporal dementia and motor neuron disease. Age at onset ranged from 23 to 56 years (mean 40.8) with a mean duration until death of 4.5 years.

see page 1376

The accompanying editorial by DeKosky and Ikonomovic notes that this article adds to the evidence that the most common mechanism of chronic neurodegenerative disorders involves abnormal protein production, processing, or misfolding, and subsequent accumulation in the brain. Specific neurons manifest selective vulnerability to specific protein processing abnormalities, for example, altered tau metabolism is associated with FTD AD, corticobasal degeneration, and progressive supranuclear palsy. In NIFID light, medium, and heavy (molecular weight) NF triplet proteins (NF-L, NF-M, and NF-H), a type IV IF protein, and {alpha}-internexin accumulate in a subset of patients with clinical features of FTD or CBD. Relatively young age at onset and faster progression of the disease, absence of family history of FTD, extrapyramidal symptomatology, diffuse hyperreflexia, and supranuclear ophthalmoplegia were suggestive of the diagnosis.

Thus, while NIFID may be an immunohistopathologically distinct form of FTD, its clinical manifestations are not unique. A biomarker is needed as well as an understanding of these mechanisms of NF aggregation.

see page 1348

Prevalence of probable migraine in a health care plan

Probable migraine (PM) is a migraine subtype lacking just one migraine feature. Patel et al. found that PM is as prevalent as migraine in a health plan and was associated with similar disability and impairment in quality of life.

see page 1432

Cerebral vascularization configuration is associated with deep WMLs

Van der Grond et al. found that vascular variations in the circle of Willis are independently associated with the deep WML load in the brain. A fetal configuration of the posterior part of the circle of Willis appeared to protect against WMLs.

see page 1452

Peripheral neuropathy after gastric bypass surgery

Bariatric gastric bypass surgery is being done increasingly to treat obesity. Thaisetthawatkul et al. characterized the neuropathy occurring after gastric bypass in 435 patients vs the neuropathy occurring after another abdominal surgery (cholecystectomy). Neuropathy occurred in 16% of patients vs only 3% of cholecystectomy controls. No specific subtype was identified: mononeuropathy, polyneuropathy, and radiculopathy all occurred.

see page 1462

The PINK1 gene in Irish Parkinson disease

Mutations in the PINK1 gene, which encodes a mitochondrial protein, have recently been reported to cause autosomal recessive Parkinson disease. In this study, Healy et al. found a low prevalence of PINK1 mutations in a large sample of Irish Parkinson disease patients.

see page 1486

PARK6-linked parkinsonism in Asian populations

Hatano et al. report that eight families including three Japanese, two Taiwanese, one Turkish, one Israeli, and one Philippine showed evidence of linkage to PARK6, indicating its worldwide distribution.

see page 1482

The editorial by Andrew Singleton accompanying these two articles notes that there are now 10 PARK loci of which four have defined gene mutations associated with parkinsonism (PARK-1, -2, -6, and -7). PINK1 disease, like that caused by parkin mutation, is recessive, suggesting that loss of protein function is key. The pathogenic relevance of single heterozygous mutations as reported may remain a contentious issue. However, it is possible that the PINK1 mutation in the heterozygous state may lead to a dopaminergic deficit that predisposes to disease much as suggested in parkin heterozygotes.

see page 1350

Considering measles SSPE in the differential diagnosis of encephalitis

Honarmand et al. describe five cases of SSPE occurring in the 16,400 cases of the California Encephalitis Project. The diagnosis of SSPE was not considered by clinicians in three of the five cases—-ADEM being mistakenly diagnosed.

see page 1489

The accompanying editorial by James Bale notes that measles is rare in the United States and SSPE, its most serious complication, occurs in 1/million children. However, in many other countries, immunization is less widespread, leading to approximately 21 SSPE cases/million in India and about 100 cases/million in Papua New Guinea. The disorder is not treatable but is preventable by measles immunization (which does not cause SSPE itself).

see page 1352

Safety of rapid infusion of valproate

The open, dose-escalation study in epilepsy patients by Wheless et al. demonstrated that rapid infusion IV of valproate at rates up to 6 mg/kg/min was well tolerated and caused no clinically important changes in blood pressure or pulse.

see page 1507

Phenytoin generic gives lower levels than brand

The FDA has considered brand and generic phenytoin equivalent. Burkhardt et al. found that in a clinical setting the small difference in bioavailability of phenytoin is magnified by non-linear kinetics. Their eight patients had a clinically important decrease in levels when switched to generic, which was reversed by restarting brand.

see page 1494


Related Articles

NIFID: A new molecular pathology with a frontotemporal dementia phenotype
Steven T. DeKosky and Milos D. Ikonomovic
Neurology 2004 63: 1348-1349. [Full Text] [PDF]

What does PINK1 mean for Parkinson diseases?
Andrew Singleton
Neurology 2004 63: 1350-1351. [Full Text] [PDF]

Subacute sclerosing panencephalitis: A preventable disease that needs to be prevented
James F. Bale, Jr.
Neurology 2004 63: 1352-1353. [Full Text] [PDF]

Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease
N. J. Cairns, M. Grossman, S. E. Arnold, D. J. Burn, E. Jaros, R. H. Perry, C. Duyckaerts, B. Stankoff, B. Pillon, K. Skullerud, F. F. Cruz-Sanchez, E. H. Bigio, I. R.A. Mackenzie, M. Gearing, J. L. Juncos, J. D. Glass, H. Yokoo, Y. Nakazato, S. Mosaheb, J. R. Thorpe, K. Uryu, V. M.-Y. Lee, and J .Q. Trojanowski
Neurology 2004 63: 1376-1384. [Abstract] [Full Text] [PDF]

Prevalence and impact of migraine and probable migraine in a health plan
N. V. Patel, M. E. Bigal, K. B. Kolodner, C. Leotta, J. E. Lafata, and R. B. Lipton
Neurology 2004 63: 1432-1438. [Abstract] [Full Text] [PDF]

A fetal circle of Willis is associated with a decreased deep white matter lesion load
J. van der Grond, A. F. van Raamt, Y. van der Graaf, W. P.T.M. Mali, and R. H.C. Bisschops
Neurology 2004 63: 1452-1456. [Abstract] [Full Text] [PDF]

A controlled study of peripheral neuropathy after bariatric surgery
P. Thaisetthawatkul, M. L. Collazo-Clavell, M. G. Sarr, J. E. Norell, and P. J.B. Dyck
Neurology 2004 63: 1462-1470. [Abstract] [Full Text] [PDF]

PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations
Y. Hatano, K. Sato, B. Elibol, H. Yoshino, Y. Yamamura, V. Bonifati, H. Shinotoh, M. Asahina, S. Kobayashi, A. R. Ng, R. L. Rosales, S. Hassin-Baer, Y. Shinar, C. S. Lu, H. C. Chang, Y. H. Wu-Chou, F. B. Ataç, T. Kobayashi, T. Toda, Y. Mizuno, and N. Hattori
Neurology 2004 63: 1482-1485. [Abstract] [Full Text] [PDF]

PINK1 (PARK6) associated Parkinson disease in Ireland
D. G. Healy, P. M. Abou-Sleiman, J. M. Gibson, O. A. Ross, S. Jain, S. Gandhi, D. Gosal, M. M.K. Muqit, N. W. Wood, and T. Lynch
Neurology 2004 63: 1486-1488. [Abstract] [Full Text] [PDF]

Subacute sclerosing panencephalitis in the differential diagnosis of encephalitis
S. Honarmand, C. A. Glaser, E. Chow, J. J. Sejvar, C. P. Preas, G. C. Cosentino, H. T. Hutchison, and W. J. Bellini
Neurology 2004 63: 1489-1493. [Abstract] [Full Text] [PDF]

Lower phenytoin serum levels in persons switched from brand to generic phenytoin
R. T. Burkhardt, I. E. Leppik, K. Blesi, S. Scott, S. R. Gapany, and J. C. Cloyd
Neurology 2004 63: 1494-1496. [Abstract] [Full Text] [PDF]

Rapid infusion with valproate sodium is well tolerated in patients with epilepsy
J. W. Wheless, B. R. Vazquez, A. M. Kanner, R. E. Ramsay, L. Morton, and J. M. Pellock
Neurology 2004 63: 1507-1508. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS